Historical Valuation
Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.98 is considered Undervalued compared with the five-year average of -26.33. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 1159.57 to 1166.07 according to relative valuation methord. Compared to the current price of 26.26 USD , Apellis Pharmaceuticals Inc is Undervalued By 97.74%.
Relative Value
Fair Zone
1159.57-1166.07
Current Price：26.26
97.74%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Apellis Pharmaceuticals Inc (APLS) has a current Price-to-Book (P/B) ratio of 8.15. Compared to its 3-year average P/B ratio of 20.54 , the current P/B ratio is approximately -60.29% higher. Relative to its 5-year average P/B ratio of 16.00, the current P/B ratio is about -49.02% higher. Apellis Pharmaceuticals Inc (APLS) has a Forward Free Cash Flow (FCF) yield of approximately 2.40%. Compared to its 3-year average FCF yield of -6.34%, the current FCF yield is approximately -137.89% lower. Relative to its 5-year average FCF yield of -7.06% , the current FCF yield is about -134.05% lower.
P/B
Median3y
20.54
Median5y
16.00
FCF Yield
Median3y
-6.34
Median5y
-7.06
Competitors Valuation Multiple
AI Analysis for APLS
The average P/S ratio for APLS competitors is 755.12, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS.O) exhibits a P/S ratio of 3.98, which is -99.47% above the industry average. Given its robust revenue growth of 132.98%, this premium appears sustainable.
Performance Decomposition
AI Analysis for APLS
1Y
3Y
5Y
Market capitalization of APLS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of APLS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is APLS currently overvalued or undervalued?
Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.98 is considered Undervalued compared with the five-year average of -26.33. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 1159.57 to 1166.07 according to relative valuation methord. Compared to the current price of 26.26 USD , Apellis Pharmaceuticals Inc is Undervalued By 97.74% .
What is Apellis Pharmaceuticals Inc (APLS) fair value?
APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 1159.57 to 1166.07 according to relative valuation methord.
How does APLS's valuation metrics compare to the industry average?
The average P/S ratio for APLS's competitors is 755.12, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of 3.98, which is -99.47% above the industry average. Given its robust revenue growth of 132.98%, this premium appears sustainable.
What is the current P/B ratio for Apellis Pharmaceuticals Inc (APLS) as of Jan 10 2026?
As of Jan 10 2026, Apellis Pharmaceuticals Inc (APLS) has a P/B ratio of 8.15. This indicates that the market values APLS at 8.15 times its book value.
What is the current FCF Yield for Apellis Pharmaceuticals Inc (APLS) as of Jan 10 2026?
As of Jan 10 2026, Apellis Pharmaceuticals Inc (APLS) has a FCF Yield of 2.40%. This means that for every dollar of Apellis Pharmaceuticals Inc’s market capitalization, the company generates 2.40 cents in free cash flow.
What is the current Forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) as of Jan 10 2026?
As of Jan 10 2026, Apellis Pharmaceuticals Inc (APLS) has a Forward P/E ratio of -17.57. This means the market is willing to pay $-17.57 for every dollar of Apellis Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Apellis Pharmaceuticals Inc (APLS) as of Jan 10 2026?
As of Jan 10 2026, Apellis Pharmaceuticals Inc (APLS) has a Forward P/S ratio of 3.98. This means the market is valuing APLS at $3.98 for every dollar of expected revenue over the next 12 months.